Eli Lilly presents new EBGLYSS data from Phase 3 ADorable-1 pediatric atopic dermatitis study at Fall Clinical 2026
LLY•Eli Lilly outlined 21 dermatology presentations scheduled for Oct. 8-11 at Fall Clinical 2026, including new data on EBGLYSS, Taltz and Zepbound.
1. Planned presentations
EBGLYSS posters will focus on durable disease control, less frequent maintenance dosing and reduced reliance on topical treatments in moderate-to-severe atopic dermatitis. Analyses from TOGETHER-PsO will assess tirzepatide added to ixekizumab in psoriasis with obesity, including biomarker readouts and cardiovascular risk factors; BRAVE-AA-PEDS updates will present longer-term outcomes for Olumiant in adolescents with severe alopecia areata.
